Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma (Nasal-LPS)

National Jewish Health logo

National Jewish Health

Status and phase

Not yet enrolling
Phase 1


Asthma; Eosinophilic


Drug: Lipopolysaccharides

Study type


Funder types




Details and patient eligibility


A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.

Full description

Patients with severe asthma can be broadly classified into three endotypes (T2, T1, and T17) based on inflammatory cell and cytokine profiles. Within these endotypes, many patients have high levels of neutrophils in the airways and mucosal epithelium. Our preliminary data suggest that neutrophils in the airways and blood of patients with severe asthma are heterogenous and that subsets exist. The nature of these subsets appears to differ between T2, T1, and T17 asthma endotypes. In order to advance the field and determine the mechanisms that underpin severe neutrophilic asthma, investigators plan to longitudinally assess transcriptional profiles and functional properties of neutrophil subsets that migrate to the nasal cavity following exposure to a standardized dose of Clinical Reference Center endotoxin (IRB#HS-3131-528, IND 018580). Investigators will recruit 15 subjects of each asthma endotype (45 total participants with asthma) and 15 healthy controls. LPS will be used to elicit migration of neutrophils into the nasal cavities. Neutrophils will be isolated from the nasal cavities using both nasal lavage and nasal brushes 20 minutes, 1 day and 3 days after endotoxin challenge. Neutrophil biology will be assessed using single-cell RNAseq and ex vivo functional assays.


60 estimated patients




18+ years old


Accepts Healthy Volunteers

Inclusion criteria

  • Participants will have asthma diagnosed by a health care provider. Healthy controls are individuals without asthma.
  • Written informed consent

Exclusion criteria

  • Current or recent illness (in the past 4 weeks)
  • Recent asthma exacerbation (past 4 weeks)
  • History of nasal perforation or nasal surgery
  • Nasal polyposis
  • Presence or prior history of cardiac or systemic disease
  • Bleeding disorder, use of systemic anticoagulants, or antiplatelet therapy
  • Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants excluding corticosteroids)
  • Use of tobacco or marijuana in the past 2 months or greater than a 10 pack-year smoking history
  • Currently pregnant or breastfeeding

Trial design

Primary purpose

Basic Science



Interventional model

Parallel Assignment


None (Open label)

60 participants in 2 patient groups

Asthma Group
Active Comparator group
Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).
Drug: Lipopolysaccharides
Control Group
Active Comparator group
Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.
Drug: Lipopolysaccharides

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems